Beyond DNA: The unseen genome and novel omics approaches to PH

A PVRI 2024 Digital webinar

Presentations 

• MicroRNAs and IncRNAs in right heart hypertrophy and failure Francois Potus
• LncRNA as biomarkers/therapeutic agents for pulmonary diseases - prospective view Stephen Chen 
• Epigenomics in pulmonary vascular remodelling Soni Savai-Pullamsetti 
• Multiomic tools for single cell analysis Herbert Schiller
• Proteomics: From discovery research toward the clinic - novel AI perspectives? Christopher Rhodes 

Polls

1. Do you think that miRNAs and lncRNAs are ready for drug development in PAH?

Yes - 33.33%

No - 66.67%

2. Could the use of lncRNAs as biomarkers help in PAH risk stratification and treatment decisions?

Yes - 81.48%

No - 18.52%

3. Targeting epigenetic mechanisms represents a well validated approach for drug development in PAH

Agree - 66.67%

Disagree - 33.33%

4. We can derive predictive protein signatures in peripheral body fluids that reflect specific cell and tissue states in diseased organs

Agree - 89%

Disagree - 11%

5. Artificial intelligence holds the key to mechanistic biomarker discovery and novel targets in PAH

Agree - 74%

Disagree - 26%